SUSVIMO: cost and payments to doctors
What Medicare Part D paid pharmacies for SUSVIMO, and the payments that named it as the associated drug or biological under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Genentech USA, Inc.?
Genentech USA, Inc. reported the most payments naming SUSVIMO. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $2.3M
- Providers
- 1,902
- Transactions
- 5,864
- Average per transaction
- $392
The per-transaction average — $392 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 1,902 providers the average total is $1,208, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Genentech USA, Inc. | $1,812,576 | 78.9% |
| Genentech, Inc. | $298,079 | 13.0% |
| F. Hoffmann-la Roche AG | $132,288 | 5.8% |
| Roche Products Limited | $44,142 | 1.9% |
| Hoffmann-la Roche Limited | $11,234 | 0.5% |
Other products from Genentech USA, Inc.
The company that reported the most payments naming SUSVIMO also reports against these.